Jul 2026· Biophysical Journal· Vol 125, pp. 4027-4043· 0 citations
Medicine
TL;DR
The correlation between SARS-CoV-2 FP conformational and multi-phase cellular membrane dynamical heterogeneity, using existing and new membranotropic parameters, that drives enhanced SARS-CoV-2 FP fusogenicity is identified.
Abstract
There are a large class of enveloped viruses that utilize sophisticated fusion mechanisms as a precursor to enter host cells. In SARS-Cov-2 the S2 domain of the S protein contains the fusion peptide (FP), which is believed to be central to the inter-membrane fusion machinery. However, the microscopic parameters that drive enhanced fusogenicity of the SARS-CoV-2 FP on realistic complex cellular membranes, leading to the observed virulence and fatality due to SARS-CoV-2 infection remains unclear. In this report, we identify the correlation between SARS-CoV-2 FP conformational and multi-phase cellular membrane dynamical heterogeneity, using existing and new membranotropic parameters, that drives enhanced SARS-CoV-2 FP fusogenicity. Combining high-resolution fluorescence microscopy and time-domain spectroscopy along with atomic molecular dynamics (MD) simulations, we demonstrate significantly enhanced membranotropy of SARS-CoV-2 FP in phase-separated model host cell membranes compared to their homogeneous counterparts. We observe dynamic phase homogenization and strongly correlated peptide-lipid diffusion, which correlates with the broader spectrum of interactions of SARS-CoV-2 FP with both the Lo and Ld, phases in the multi-phase complex model cellular membranes. Significantly, we correlate SARS-CoV-2 binding heterogeneity with lipid-mixing data to demonstrate how the FP's conformational binding landscape modulates key fusogenic parameters such as membrane fluidity and dehydration, leading to enhanced macroscopic fusion. Our findings offer a mechanistic framework that extends existing paradigms of viral fusion peptide activity to heterogeneous membrane environments, potentially informing the development of broadly acting antiviral strategies targeting the fusion machinery.
ABSTRACT SARS-CoV-2 entry into host cells is mediated by the spike glycoprotein, which promotes fusion between viral and host membranes. Despite its importance, the precise location and mode of action of the fusion peptide, a key spike region that inserts into and perturbs the host membrane, remain elusive. Two regions...
Carolina C. Buga, Mariana Valério, M. Alenquer et al.· Journal of Virology· 0 citations
It is demonstrated that N protein-vgRNA condensates are spontaneously enveloped by lipid bilayer membranes, whereas condensates formed by N protein alone or with genomic RNA fragments fail to undergo envelopment and instead adhere to or weakly deform membranes.
Rini Ravindran, Benjamin Guérin, Ahmad Mahmood et al.· bioRxiv· 0 citations
It is demonstrated that nanobodies targeting the PLpro/ISG15 interface can achieve synergistic antiviral and immunomodulatory effects, providing a proof-of-concept for a novel therapeutic approach to combat SARS-CoV-2 and potentially other emerging coronaviruses.
Guo-Long Liu, Jian-Tao Chen, Fang Wu et al.· Journal of Virology· 0 citations
The results show the value of nanobody technology for identifying novel neutralising epitopes in the S2 region of beta-coronaviruses with potential for the development of new selective anti-viral agents.
John D. Clarke, Luke M. Jones, Imogen I. H. Buckle et al.· Scientific Reports· 0 citations
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) highlighted the need for experimental systems that enable investigation of viral replication, assembly, and host-virus interactions while minimizing the biosafety constraints associated with infectious virus. Although authentic SARS-CoV-2 remains the gold sta...
HRBD demonstrated potent and broad-spectrum inhibition against Pangolin-CoV, SARS-CoV, SARS-CoV, SARS-CoV-2, and its variants, lowering the half-maximal inhibitory concentration (IC50) by approximately 1000-fold compared to the monomeric RBD.
Jintao Zou, Lingyu Su, Jian-Sheng Lu et al.· Antiviral Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.